We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

Michel Dahan Biography and Net Worth

COO of Akebia Therapeutics

Michel Dahan joined Akebia in 2013 and is Senior Vice President, Chief Operating Officer. Mr. Dahan previously served as our Chief Business Officer. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., most recently as Vice President, Commercial Development and Strategic Planning, and led global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France), and he completed an executive education program (PLD) at Harvard Business School.

What is Michel Dahan's net worth?: The estimated net worth of Michel Dahan is at least $1.33 million as of February 29th, 2024. Mr. Dahan owns 706,932 shares of Akebia Therapeutics stock worth more than $1,325,498 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Dahan may own. Learn More about Michel Dahan's net worth.
How do I contact Michel Dahan?: The corporate mailing address for Mr. Dahan and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Michel Dahan's contact information.
Has Michel Dahan been buying or selling shares of Akebia Therapeutics?: Michel Dahan has not been actively trading shares of Akebia Therapeutics during the last quarter. Most recently, Michel Dahan sold 8,661 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.58, for a transaction totalling $13,684.38. Following the completion of the sale, the chief operating officer now directly owns 706,932 shares of the company's stock, valued at $1,116,952.56. Learn More on Michel Dahan's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 187,893 shares worth more than $300,597.66. The most recent insider tranaction occured on February, 29th when COO Michel Dahan sold 8,661 shares worth more than $13,684.38. Insiders at Akebia Therapeutics own 4.1% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 2/29/2024.

Michel Dahan Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/29/2024	Sell	8,661	$1.58	$13,684.38	706,932
2/27/2024	Sell	10,744	$1.52	$16,330.88	715,593
5/25/2023	Sell	95,478	$1.22	$116,483.16	574,037
3/1/2023	Sell	20,412	$0.88	$17,962.56	269,515
2/28/2022	Sell	6,555	$2.15	$14,093.25
4/1/2021	Sell	1,211	$3.40	$4,117.40
2/28/2020	Sell	6,972	$8.70	$60,656.40	211,932
10/2/2017	Sell	1,398	$19.64	$27,456.72
9/28/2017	Sell	5,000	$19.30	$96,500.00	97,224
8/15/2017	Sell	5,000	$15.00	$75,000.00	102,224
4/4/2016	Sell	1,401	$9.41	$13,183.41	74,956

Michel Dahan Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.88

$1.86

$1.90

50 Day Range

MA: $1.77

$1.28

$2.13

2 Week Range

Now: $1.88

$0.80

$2.48

Volume

614,034 shs

Average Volume

3,008,998 shs

Market Capitalization

$409.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

The #1 Crypto for AI

From Weiss Ratings | Ad